AstraZeneca followed a long and arduous road to bring its CTLA4 inhibitor Imjudo to market, and will now have to defend its new product from a patent infringement complaint brought by Brist
It looks like Astellas has been unsuccessful in its attempt to block Pfizer's generic medicines unit Hospira from launching a copycat version of big-selling pharmacologic stress agent Lexis
In a dramatic change in fortunes, Novartis has won a major victory in its bid to defend oral multiple sclerosis therapy Gilenya from early generic competition in the US.
Astellas has won a reprieve in its attempt to stop Pfizer's generic medicines unit Hospira launching a copycat version of its pharmacologic stress agent Lexiscan in the US – but only for a
A Texas court has confirmed the $41.8 million damages awarded to Seagen in its patent dispute with Daiichi Sankyo over beast cancer drug Enhertu, but declined to raise the sum despite concl
It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.